COPENHAGEN, October 9, 2025 – Novo Nordisk (NVO) agreed to acquire Akero Therapeutics for 4.7 billion upfront, marking a major expansion into liver disease treatment.

The deal provides Novo access to efruxifermin, Akero’s late-stage drug candidate for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver condition affecting millions globally.

  • Novo pays 54 per share, 19% premium to recent trading
  • Additional 500 million contingent on drug approval milestones
  • Targets MASH market with potential multi-billion revenue opportunity

Market reaction & context

Akero Therapeutics (AKRO) shares surged following the announcement, while Novo Nordisk stock declined as investors weighed the acquisition cost8. The 54-per-share offer represents a 19% premium to Akero’s 30-day volume-weighted average price1.

The acquisition adds to a surge in MASH dealmaking as pharmaceutical companies race to capture share in the emerging liver disease market. Novo’s move follows similar investments by competitors targeting the same therapeutic area4.

Strategic rationale

The deal centers on efruxifermin, an FGF21 analogue currently in phase 3 trials for MASH treatment6. MASH affects an estimated 115 million people globally and represents a significant unmet medical need with limited approved therapies.

Novo’s acquisition strategy aligns with its broader push beyond diabetes and obesity treatments. The company sees efruxifermin as complementary to its existing GLP-1 portfolio, potentially offering combination treatment approaches3.

Transaction details

Under the agreement, Novo will pay 4.7 billion upfront at 54 per share, with an additional contingent value right worth 500 million or 6 per share tied to regulatory approval milestones7. The total potential transaction value reaches 5.2 billion if all milestones are achieved.

California-based Akero shareholders will receive the upfront payment upon closing, expected in the coming months subject to regulatory approvals and customary closing conditions4. The deal requires approval from Akero shareholders and antitrust authorities.

Market opportunity

MASH represents a substantial commercial opportunity as the most common chronic liver disease in developed countries. Current treatment options remain limited, creating space for innovative therapies like efruxifermin to capture significant market share.

Analysts view the liver disease market as potentially worth billions annually, driven by rising obesity rates and metabolic disorders that contribute to MASH development. Novo’s entry positions the company to compete for this emerging revenue stream alongside its established diabetes franchise.

Not investment advice. For informational purposes only.

References

1“Akero Therapeutics to be Acquired by Novo Nordisk for up to 5.2 Billion”. Akero Therapeutics IR. Retrieved October 9, 2025.

2“Novo to buy Akero for up to 5.2 billion in new CEO’s revival push”. Reuters. Retrieved October 9, 2025.

3“Novo inks 4.7B Akero buyout to bag late-phase MASH prospect”. FierceBiotech. Retrieved October 9, 2025.

4“Novo joins MASH dealmaking surge with 4.7B Akero buyout”. BioPharma Dive. Retrieved October 9, 2025.

5“Novo Nordisk to Acquire Akero Therapeutics for Up to 5.2 Billion”. Wall Street Journal. Retrieved October 9, 2025.

6“Novo Nordisk Enters 4.7 Billion Definitive Agreement with Akero Therapeutics”. PharmExec. Retrieved October 9, 2025.

7“Novo Nordisk is paying up to 5.2 billion for a San Francisco biotech working on liver disease”. MarketWatch. Retrieved October 9, 2025.

8“Novo Nordisk Is Buying Biotech Akero Therapeutics. The Stock Soars.”. Barron’s. Retrieved October 9, 2025.

9“Novo Nordisk to Acquire Akero Therapeutics for 4.7 Billion to Advance MASH Treatment Portfolio”. GeneOnline. Retrieved October 9, 2025.